Affidea

What Affidea does

Affidea Group BV is a pan-European outpatient healthcare platform operating more than 300 diagnostic imaging, polyclinic, cancer care, and laboratory centers across 15 countries, headquartered in Amsterdam, Netherlands. Founded in 1991, the company employs approximately 11,000 healthcare professionals (including 4,000+ doctors) and serves more than 10 million patients per year, performing over 14 million diagnostic examinations annually. Its service portfolio spans advanced diagnostic imaging (MRI, CT, PET-CT, mammography, X-ray, nuclear medicine), outpatient polyclinic and specialist consultations, cancer care (radiotherapy via Elekta and TrueBeam linear accelerators, chemotherapy), laboratory analysis, occupational health, and sports medicine through its Fortius Clinic subsidiary in the UK.

The underlying technology stack combines state-of-the-art imaging hardware with a digital infrastructure anchored by Oracle Fusion Cloud HCM for workforce management, the 'My Affidea' patient portal for digital registration and longitudinal records, and the DoseWatch 3.2 / Azure BI platform for radiation dose monitoring and clinical benchmarking. AI capabilities are integrated via partnerships with Subtle Medical (PET/CT), icometrix (brain imaging), Aidence (lung imaging), Skin Analytics (DERM dermatology), and b-rayZ / Biotronics3D (breast imaging), positioning Affidea as a preferred deployment partner rather than a model developer. Clinical governance follows an Integrated Clinical Governance Model recognized by Joint Commission, DNV, and Eurosafe.

Revenue is generated primarily on a fee-for-service basis across six streams: diagnostic imaging, outpatient polyclinics, cancer care, laboratory services, occupational/corporate health, and sports medicine. Customers include private health insurers (under capitation and FFS arrangements), national health systems (NHS and equivalents), over 8,000 corporate clients (notably in Italy), and self-pay patients, in an approximately 45/55 private/public payor mix. Distribution is exclusively direct through the owned center network supplemented by teleradiology for cross-border diagnostic coverage. Following the 2022 majority stake acquisition by Groupe Bruxelles Lambert (GBL) for up to EUR 1.0 billion, the company has pursued an aggressive M&A-led expansion strategy, completing over 20 acquisitions through 2026 including Gruppo CDC (Italy), Fortius Clinic (UK), Brust-Zentrum Zürich, MedEuropa Romania, Nu-Med Group Poland, Uroviva, and LabPoint S.A.

Name

Affidea

Legal name

Affidea Group BV

Website

https://affidea.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Affidea is a pan-European outpatient healthcare platform operating 300+ diagnostic imaging, polyclinic, and cancer care centers across 15 countries, serving over 10 million patients annually through ~11,000 professionals under majority owner Groupe Bruxelles Lambert (GBL).

Ownership category

akta.pro rank

Product category

Diagnostic Imaging Services

NAICS

Diagnostic Imaging Centers (621512), Ambulatory Health Care Services (621)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB)

akta.pro secondary industries

Radiology Imaging Centers (X-ray/CT/MRI/Ultrasound) (HLAFAKAA), Virtual Specialty Care Platforms (tele-stroke, tele-ICU, tele-derm, tele-cardiology) (HLALABAD), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ)

Keywords

• Diagnostic imaging services
• Outpatient polyclinic services
• Cancer care services
• Teleradiology network
• Occupational health services

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices17 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostic Imaging Services: Fee-for-service revenue from MRI, CT, PET-CT, mammography, X-ray, and other diagnostic imaging examinations. Billed to private health insurers, public healthcare systems, corporations (occupational health), and self-pay patients.
2. Outpatient Polyclinic and Specialist Consultations: Revenue from multi-specialty outpatient consultations, day surgery, physiotherapy, and rehabilitation services. Mix of private pay, PHIs, and NHS/public payors.
3. Cancer Care Services: Radiotherapy and chemotherapy services, including linear accelerator treatments. Revenue from public healthcare systems and private insurers.
4. Laboratory Analysis Services: Blood tests, genetic testing, molecular biology, cytogenetics, and pathology services across laboratory network.
5. Occupational Health / Corporate Health Services: B2B contracts with private companies for employee health check-ups, screening, and corporate wellness programs. Capitation model with PHIs.
6. Sports Medicine and Orthopaedics: Specialized orthopaedic, musculoskeletal, and sports medicine services through Fortius Clinic, serving elite athletes, sports clubs, and general patients.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels8 records

Core offering

Affidea is the pan-European provider of advanced diagnostic imaging (MRI, CT, PET-CT, mammography, X-ray, nuclear medicine), community-based multi-specialty outpatient polyclinics, cancer care (radiotherapy and chemotherapy), laboratory analysis, occupational/corporate health, and sports medicine/orthopaedics, delivered through an owned network of more than 300 centers across 15 European countries, supported by teleradiology and digital patient-pathway systems.

Product overview

Affidea is a pan-European healthcare platform operating 320+ diagnostic imaging and outpatient centers across 15 countries. The integrated offering combines advanced diagnostic imaging (MRI, CT, PET-CT, mammography, X-ray, nuclear medicine) with community-based polyclinics providing multi-specialty consultations, laboratory services, and radiotherapy/oncology treatments. Key acquired brands include Fortius Clinic (UK orthopedics/MSK), Brust-Zentrum Zürich (Swiss breast care), and Gruppo CDC (Italian diagnostics). Technology-enabled services include the Dose Excellence Program for radiation monitoring, AI-powered imaging via partnerships with Subtle Medical, b-rayZ, and Skin Analytics, and the neuraCare neurology network. The platform serves over 10 million patients annually through ~11,000 healthcare professionals.

Differentiator

Problem solved

Functional benefit

Brands

• Fortius Clinic: UK's largest orthopaedic group specializing in musculoskeletal care and sports medicine, part of Affidea Group
• Brust-Zentrum Zürich
• Gruppo CDC
• LabPoint
• neuraCare

Products and services

• Advanced Diagnostic Imaging
• Community-based Polyclinics
• Cancer Care Services
• neuraCare Neurology Centers of Excellence
• Roczen Digital Health Platform
• Teleradiology Services
• Laboratory Services
• Fortius Clinic Orthopedic and Sports Medicine Services
• Brust-Zentrum Zürich Breast Care
• AI-Integrated Breast Imaging Workflow
• Affidea Wimbledon Private Clinic
• Occupational Health and Corporate Health Services
• Clinical Research

Quantifiable outcome

• 33% reduction in FDG dose for PET/CT scans using SubtlePET AI without compromising image quality
• +8 more outcomes

Named customers7 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature10 records

Partnerships

18 partnerships are on record, tiered strategic, minor and core.

• Skin AnalyticsstrategicTechnology or Integration · 18 August 2025Affidea partnered with Skin Analytics to implement AI-based skin cancer detection technology (DERM) across several European countries, starting with Romania and Lithuania. The collaboration aims to improve early diagnosis and patient access to skin cancer care, with plans to expand further across Europe.
• b-rayZstrategicTechnology or Integration · 30 June 2025Affidea selected b-rayZ as its preferred AI partner in breast imaging in a strategic move to improve patient outcomes in breast cancer. The partnership was announced at RSNA 2025 and covers AI-integrated breast imaging workflow across Affidea's European network.
• Uroviva GroupstrategicStrategic or Co-development Partner · 3 April 2025Affidea doubled its size in Switzerland through the acquisition of Uroviva Group, becoming one of the top outpatient healthcare providers in the country. This followed the LabPoint acquisition strategy of building integrated precision medicine.
• Reset HealthstrategicStrategic or Co-development Partner · 4 November 2024Affidea Group partnered with Reset Health to launch the Roczen platform across its network — a clinically-led digital weight loss and diabetes management solution. This represents Affidea's entry into digital health therapeutics for metabolic conditions.
• Nu-Med GroupstrategicStrategic or Co-development Partner · 9 October 2024Affidea completed the acquisition of Nu-Med Group in Poland, a cancer care group. This expanded Affidea's cancer care services in Poland, building on its existing radiotherapy capabilities and TrueBeam centers.
• MedEuropa RomaniastrategicStrategic or Co-development Partner · 21 May 2024Affidea completed the acquisition of MedEuropa Romania — a cancer care provider operating four clinics across Romania with a new facility under construction. Combined with the opening of a new €15 million radiotherapy centre in Iasi featuring Elekta linear accelerators, this significantly enhanced Affidea's oncology footprint in Romania.
• Clínica Radiologia de AlbufeiraminorStrategic or Co-development Partner · 5 July 2023Affidea acquired Clínica Radiologia de Albufeira in Portugal, marking its expansion into the Algarve region and enhancing its radiology and outpatient service portfolio in southern Portugal.
• Clínica do Coração do AlentejominorStrategic or Co-development Partner · 5 July 2023Affidea acquired Clínica do Coração do Alentejo in Portugal, marking its expansion into the Evora region and enhancing its cardiology and outpatient services in the Alentejo region.
• Brust-Zentrum ZürichstrategicStrategic or Co-development Partner · 12 April 2022Affidea acquired a majority stake in Brust-Zentrum Zürich, the largest integrated breast medicine group in Switzerland. The three founders (Prof. Christoph Tausch, Prof. Jian Farhadi, Onko-Zentrum) continue as shareholders and board members. The partnership expands Affidea's women's health services across Switzerland and Europe.
• Rugby Players Association (RPA)minorGTM or Marketing Partner · 4 April 2022Fortius Clinic (UK, part of Affidea Group) renewed its official partnership with the Rugby Players Association for the second consecutive year. Fortius provides world-class orthopaedic and sports medicine care to over 800 current and 400 former professional rugby players in England.
• Spire St Anthony's HospitalminorStrategic or Co-development Partner · 21 March 2022Fortius Clinic (part of Affidea Group) partnered with Spire St Anthony's Hospital to launch a second Joint Replacement Centre in Southwest London. The center provides Mako robotic-assisted hip and knee replacement surgery to private and self-pay patients.
• OraclecoreTechnology or Integration · 10 February 2022Affidea implemented Oracle Fusion Cloud Human Capital Management (HCM) as its global HRIS system across all 15 countries. Oracle Consulting guided the country-by-country rollout. The system provides standardized HR processes, talent management, clinical education tracking, and supports teleradiology and telehealth workforce management.
• Promea SpA (acquisition)strategicStrategic or Co-development Partner · 10 January 2022Affidea acquired 100% of Promea Center in Turin, Italy — an outpatient provider specializing in outpatient services, day surgery, and genetics. The acquisition added cytogenetics and molecular biology laboratory for genetic screening and medically assisted procreation services.
• Hillsborough Private ClinicminorStrategic or Co-development Partner · 4 November 2021Affidea acquired Hillsborough Private Clinic in Northern Ireland, expanding its diagnostics and treatment capacity. The clinic performs approximately 4,000 surgical procedures and 11,000 outpatient attendances annually, offering cataract surgery, endoscopic surgery, and general surgical procedures.
• GE HealthcarecoreTechnology or Integration · 3 August 2021Affidea and GE Healthcare partnered to launch DoseWatch 3.2 combined with a real-time Business Intelligence tool for radiation dose monitoring. This is described as celebrating 'ten years of collaboration in advancing Dose Excellence in Europe.' GE Healthcare provides the DoseWatch software and Edison platform while Affidea deploys Imaging Insights BI across its European network.
• Gruppo CDC (Centro Diagnostico Cernaia)strategicStrategic or Co-development Partner · 1 July 2021Affidea acquired 100% of Gruppo CDC in Piedmont, Italy — 32 locations, 1.2 million patients, 1,300+ professionals, 3.7 million lab tests, 420,000 specialist visits, and 500,000 diagnostic imaging exams per year. This made Affidea the largest outpatient medical provider in Italy.
• Fortius ClinicstrategicStrategic or Co-development Partner · 2 March 2021Affidea acquired Fortius Clinic, the UK's largest orthopaedic group with international reputation in orthopaedics and MSK. Fortius operates outpatient and diagnostic clinics in central London, a surgical centre, and specialist Joint Replacement Centre. The acquisition expanded Affidea to its 16th geography.
• Subtle MedicalcoreTechnology or Integration · 19 December 2019Affidea pioneered AI-powered PET/CT through a strategic partnership with Subtle Medical. SubtlePET AI software improves PET/CT image quality while reducing FDG dose by 33% or reducing scan time. The technology is operational at Affidea IRMET in Turin, Italy, with potential for wider rollout.

Scale indicators17 records

Recent moves7 records

Expansion highlights7 records

Regional players

• MedLife: Largest private healthcare operator in Romania with hospitals, outpatient clinics, labs and imaging. Direct geographic overlap with Affidea Romania and a credible local competitor in the same oncology and outpatient segments.
• Centric Health: Ireland-focused primary care, diagnostics and specialist services operator. Regional overlap with Affidea Ireland (Dundrum, Naas, Cork clinics), competing for similar PHI and self-pay outpatient volumes.

Direct peers

• Unilabs: Europe's largest clinical diagnostics and imaging provider operating across 15+ countries. Most directly comparable to Affidea in scale, geography, and combined imaging/laboratory offering; like Affidea, it is PE-backed and pursuing an aggressive pan-European M&A roll-up.
• Synlab: European medical diagnostics leader spanning clinical lab, imaging and veterinary services across 30+ countries. Closely comparable to Affidea's lab and imaging franchise; previously listed, now under Cinven ownership pursuing similar pan-European consolidation.
• Inovie: French-headquartered pan-European diagnostic platform combining medical labs, imaging and outpatient specialty care across France, Spain, Italy, Portugal and the Middle East. Closely mirrors Affidea's combined imaging/polyclinic/lab model in adjacent geographies.
• Medicover: Listed European healthcare services and diagnostics operator with clinics, labs and hospitals concentrated in CEE and Germany. Comparable outpatient and diagnostic profile to Affidea in overlapping Polish, Romanian, and German-adjacent markets.
• I-MED Radiology Network: Australia's largest diagnostic imaging network (~250 clinics). Highly comparable business model — multi-modality imaging, teleradiology, AI integration — and a useful international benchmark for Affidea's imaging-led value proposition despite geographic distance.

Broad incumbents

• Sonic Healthcare: Global diagnostics, imaging and laboratory group with European presence across Germany, UK, Switzerland, Belgium. Larger and more diversified than Affidea, but overlapping in imaging/radiology and providing a public-market read on European diagnostics multiples.
• Fresenius Medical Care: Diversified global healthcare incumbent (dialysis, hospitals, Helios/Kabi). Overlaps with Affidea through Helios/Fresenius outpatient and hospital operations in Spain and Germany, and offers a benchmark for capital-intensive healthcare services at scale.
• HCA Healthcare: Largest US for-profit hospital and outpatient operator with global consulting arm. Not a direct competitor, but a broadly comparable capital-intensive, multi-site, technology-driven healthcare services platform — useful as a scaled-services benchmark for Affidea's trajectory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat7 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/AffideaGroup
• YouTubeyoutube.com/channel/UCOWhByswpnzYdg3qAnJ9i9Q
• Facebookfacebook.com/affidea
• LinkedInlinkedin.com/company/affidea
• Instagraminstagram.com/affidea_group

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries13 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Affidea